Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
Ivana Gojo(Johns Hopkins University), Edward A. Sausville(University of Maryland, Baltimore), Kenneth S. Bauer(University of Maryland, Baltimore), Stephanie Fleckinger(University of Maryland, Baltimore), Martin Carroll(University of Pennsylvania), Selina M. Luger(University of Pennsylvania), Maria R. Baer(University of Maryland, Baltimore), Kelly J. Norsworthy(United States Food and Drug Administration), Alexander E. Perl(University of Pennsylvania), Michael Tidwell(University of Maryland, Baltimore)
Cited by 51
Related Papers
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907